Welcome to our dedicated page for NantHealth news (Ticker: NH), a resource for investors and traders seeking the latest updates and insights on NantHealth stock.
Company Overview:
NantHealth Inc. (symbol: NH) is a pioneering healthcare technology company that is transforming the landscape of personalized healthcare. The company's mission is to optimize patient outcomes and enable value-based care through advancements in technology and precision medicine.
Core Business and Offerings:
NantHealth integrates novel diagnostics with large-scale biometric and phenotypic data to deliver truly personalized healthcare solutions. By adopting a systems-based approach, NantHealth enhances treatment decisions for critical illnesses, effectively improving patient outcomes.
Recent Achievements:
The company has made significant strides in deploying its precision medicine platforms, harnessing biometric and phenotypic data. These achievements underscore NantHealth's commitment to pushing the boundaries of personalized healthcare.
Current Projects:
NantHealth is actively involved in developing and refining its healthcare platforms. The focus is on integrating advanced diagnostics with data analytics to provide actionable insights that guide treatment options, ensuring better care for patients.
Financial Condition:
While specific financial details fluctuate with market activities and quarterly reports, NantHealth remains dedicated to its financial health and sustainable growth, continually seeking to advance its mission and technology.
Partnerships:
NantHealth collaborates with various healthcare providers, research institutions, and technology companies to enhance its offerings and expand its impact on the healthcare sector.
Significance:
NantHealth's unique approach to integrating diagnostics and data analytics sets it apart in the healthcare industry. Their commitment to precision medicine has made them a significant player in the quest for more effective and personalized treatments for critical illnesses.
NantHealth (NASDAQ-GS: NH) has appointed Scott Maratea as its new Chief Revenue Officer. With over 30 years of experience in healthcare technology, Maratea has a proven track record of exceeding revenue targets and growing client relationships with leading healthcare organizations. Previously, he served as CRO at Curve Health and Life Image, Inc., demonstrating success in sales, marketing, and business development.
In his new role, Maratea will lead NantHealth's sales and revenue generation efforts, focusing on driving growth and expanding the company's market presence. His appointment is expected to help NantHealth achieve its growth objectives and continue delivering innovative healthcare solutions.
NantHealth (NASDAQ: NH) has received a 3-year reaccreditation for its Utilization Management Program from the National Committee for Quality Assurance (NCQA). This accreditation underscores the program's high standards in consumer protection and service improvement. NCQA accreditation, known for its rigorous and comprehensive standards, signifies excellence in healthcare quality and accountability. Haris Naseem, CEO of NantHealth, and Megan Salmon-Gardell, Chief Nursing Officer, emphasized that this achievement reaffirms NantHealth's commitment to superior healthcare delivery and patient outcomes.
NantHealth, Inc. (NASDAQ: NH) has achieved HITRUST Risk-based, 2-year Certified status for its Eviti Connect solution, confirming its adherence to crucial regulations and security standards.
This certification places NantHealth among a select group of organizations globally, showcasing its commitment to data protection and information security. The HITRUST Assurance Program offers comprehensive controls addressing security and data challenges, which is essential in today’s evolving threat landscape.
Ron Louks, COO of NantHealth, emphasizes their dedication to maintaining the highest data protection standards through this achievement.
NantHealth, Inc. (NASDAQ: NH) has entered into a credit agreement for a new senior secured term loan totaling $22.5 million. The funding aims to support the company's ongoing operations and general corporate needs. Investors Highbridge Capital Management and Nant Capital are providing the loan. CEO Dr. Patrick Soon-Shiong highlighted the role of artificial intelligence in transforming healthcare, while COO Ron Louks emphasized the investment's potential to enhance established solutions like NaviNet and Eviti. The company's board has unanimously endorsed the transaction.
The OpenNMS Group, a subsidiary of NantHealth (NASDAQ: NH), has announced the release of OpenNMS Meridian 2023, enhancing its network monitoring solutions. This release focuses on cloud services and containerization benefits. Key features include a scalable time series database, containerized deployment, flow thresholding for anomaly detection, native device configuration backups, and a new hardware appliance to streamline operations. OpenNMS emphasizes security with initiatives like zero-trust architecture and alignment with ISO 27001. Meridian is available as a subscription service, ensuring users have access to stable and secure monitoring capabilities.
NantHealth (NASDAQ: NH) has announced a reverse stock split of 1-for-15, effective December 15, 2022, at 5 p.m. ET. This action, approved by stockholders on August 18, 2022, aims to increase the trading price of its common stock to meet Nasdaq's minimum bid requirement. The total shares will decrease from approximately 115.5 million to about 7.7 million, while the authorized shares remain at 750 million. No fractional shares will be issued; instead, stockholders will receive cash for any fractions. The stock continues to trade under the symbol 'NH.'
NantHealth, Inc. (NH) reported Q3 2022 net revenue of $16.6 million, a 15% increase from $14.4 million in Q3 2021, marking the fourth consecutive quarter of revenue growth.
The gross profit reached $9.7 million (58% margin), the highest since Q4 2020. However, net loss increased to $13.7 million ($0.12 per share) compared to $10.8 million ($0.09 per share) in the prior year.
The company secured multiple contract renewals and extended relationships, including a three-year agreement with a national insurer covering over two million Medicaid members.
NantHealth, Inc. (NASDAQ: NH) is set to report its third-quarter financial results for 2022 on November 3, 2022, after market close. The company's management will conduct a conference call at 1:30 p.m. PT (4:30 p.m. ET) to discuss the performance details. Investors can join the call by dialing 800-942-2493 (U.S.) or 212-231-2931 (international). The call will also be available online at nanthealth.com.
FAQ
What does NantHealth Inc. do?
What is NantHealth's mission?
What recent achievements has NantHealth made?
What are some of NantHealth's current projects?
Who are NantHealth's partners?
How does NantHealth impact the healthcare industry?
What makes NantHealth's approach unique?
Is there a focus on value-based care at NantHealth?
Where can I find more information about NantHealth?
How can I stay updated on NantHealth's latest developments?
